Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Breast cancer chemo may speed up brain aging, new study suggests

NCT ID NCT02122107

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how chemotherapy and other factors affect thinking and memory in older women who survived breast cancer. Researchers will compare these women to older women who never had cancer. They will also study how genetics and smoking history play a role. About 500 women will take memory tests and surveys over two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

499 people

The number who actually took part.

Started

Apr 2014

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We propose to enroll 540 participants into the study across the 2 sites: 270 participants (approximately 180 patients and 90 controls) from MSK and 270 participants from City of Hope (approximately 180 patients, and 90 controls).

Ages

60 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The neuropsychological assessments were designed and validated in English and are not currently available in other languages. Translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. Therefore, participants must be able to communicate in English to complete the tests. Friend nominated, non-cancer controls will be frequency matched on age (+/- 5 years), education (less than college vs. some college and above), and race will be recruited using the same eligibility criteria as survivors except for no history of cancer. For cancer patients, eligibility includes: * As per medical record or self-report, post-menopausal female * As per medical record or self-report, age 60 or older at recruitment * As per medical record or self-report, age 55 or older at the time of breast cancer diagnosis * As per medical record or self report, for cancers other than breast cancer or non-melanoma/basal cell skin cancer/squamous cell skin cancer: * Patient must be at least 3 years post diagnosis of that cancer * Not received chemotherapy treatment or external beam radiation for that cancer * As per medical record or self-report, 5-15 years post diagnosis of breast cancer at the time of enrollment * As per medical record or self-report, no evidence of any cancer disease * American Joint Committee on Cancer (AJCC) stages 0-III breast cancer survivor as per clinical judgment/electronic medical record (EMR) * Score of \< 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) * In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent * English proficiency verified through an adapted Bidimensional acculturation scale, score of 2.5 or above \*\*\*The scale will only be administered to participants who report also speaking a language other than English. For controls participants, eligibility includes: * As per medical record or self-report, post-menopausal female * As per medical record or self-report, age 60 and older at recruitment * In the judgment of the consenting professional, able to communicate well enough in English through verbal and written communication to complete the study assessments and provide informed consent °English proficiency verified through an adapted Bidimensional acculturation scale, score of 2.5 or above. \*\*\*The scale will only be administered to participants who report also speaking a language other than English. * Score of \< 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) * As per self report, no history of treatment with chemotherapy * As per self report no history of cancer except non-melanoma/basal cell skin cancer squamous cell skin carcinoma Exclusion Criteria: * For cancer patients, exclusion criteria includes: * As per medical record or self report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g., Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc) * As per medical record or self report, history of stroke or head injury requiring visit to the emergency room or hospitalization * As per medical record or self report, diagnosis of major Axis I psychiatric disorder including schizophrenia, manic-depressive disorder, or substance use disorders * As per self report or in the judgment of the consenting professional, visual or auditory impairment that would preclude ability to complete assessments * As per self report or as confirmed by the medical record, if the patient is taking anti-depression or anti-anxiety medication, \< 2 months on these medication or a change in the prescribed dose in the past 2 months * Previously or actively participating in protocol MSK IRB# 10-079 * For control participants, exclusion criteria include * As per self report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g., Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc.) * As per self report, history of stroke or head injury requiring visit to the emergency room or hospitalization * As per self report, diagnosis of major Axis I psychiatric disorder including schizophrenia, manic-depressive disorder, or substance use disorder * As per self report, or in the judgment of the consenting professional, visual or auditory impairment that would preclude ability to complete assessments * As per self report,if the person is taking anti-anxiety or anit-depression medication \<2 months on these medications or a change in the prescribed dose in the past 2 months * Previously or actively participating in protocol 10-079

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.